Key facts
- PreciseDx’s last known valuation is $41.5M (Jun 2025).
- It has raised $42.8M across 2 recorded rounds; the latest was Early Stage VC ($11.2M) in May 2025.
- Notable investors include Labcorp Venture Fund, MSD Global Health Innovation Fund, GenHenn Capital, Agilent Technologies, Eventide Asset Management — 11 tracked in total.
- PreciseDx has filed 2 Form Ds with the SEC since 2024, most recently Jun 2025 ($11.2M sold to 9 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for PreciseDx
Funding rounds
2 roundsAbout PreciseDx
Developer of artificial intelligence-guided pathology diagnostics designed to improve patient outcomes in the field of cancer and other diseases. The company's commercial, regulatory, and translational research experience enables the advancement of technologies across diverse areas such as clinical modeling, patient phenotyping, image analysis, and the practical use of big data in a real-world setting, enabling patients to improve their quality of life.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2020
- Employees
- 29
- Website
- precisedx.ai/
- Ownership
- Privately Held (backing)
PreciseDx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in PreciseDx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on PreciseDx in its N-PORT filings yet. We sweep new filings monthly.